Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, DMT +4 moreLSD, psilocybin, DMT, mescaline, 5-MeO-MiPT, 4-HO-MiPT, DPT show less
MiPT
N-methyl-N-isopropyltryptamine
MiPT (N-methyl-N-isopropyltryptamine) is a synthetic psychedelic of the tryptamine class. It is the unsubstituted parent compound of the MiPT series — structurally related to DMT but orally active without additional drugs. It partially activates serotonin receptors in the brain, producing the introspective and cognitive shifts characteristic of classical psychedelics.[1]
MiPT (N-methyl-N-isopropyltryptamine) is a synthetic psychedelic of the tryptamine class. It is the unsubstituted parent compound in the MiPT series, distinguished by short duration and oral activity without MAOI co-administration. MiPT is a partial agonist at the 5-HT₂A receptor, producing its effects by disrupting serotonin-mediated filtering of sensory and cognitive input.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, DMT +4 moreLSD, psilocybin, DMT, mescaline, 5-MeO-MiPT, 4-HO-MiPT, DPT show less
Repke, Grotjahn, and Shulgin first described MiPT in 1985, demonstrating that an asymmetric nitrogen structure could bypass the enzyme that normally destroys tryptamines before they reach the brain.[2] Shulgin later documented its effects in depth in TiHKAL (1997), establishing the compound's unusual cognitive-dominant character.[3] MiPT remains exceptionally rare, with virtually no forensic or clinical reports in circulation.
Subjective effects include color brightening, auditory enhancement, flowing introspective thought, and entheogenic ideation.[2][3] The experience is defined by cognitive intensity rather than visual spectacle — clear and introspective, with remarkably little of the geometric patterning typical of tryptamines. Anxiety, confusion, and restless body load are characteristic unwanted effects.
MiPT does not produce physical dependence, and no human toxicity data exist.[4] The greatest danger is combining it with MAOIs or other serotonergic drugs, which can dramatically amplify its effects and trigger a life-threatening overheating and seizure response.[5] What is known rests almost entirely on structural inference and a small number of self-experiment accounts — direct human safety data are absent.
History[edit]
Discovery
Repke, Grotjahn, and Shulgin first described MiPT in 1985 in the Journal of Medicinal Chemistry, showing that a bulky isopropyl group on the nitrogen could block the enzyme that degrades tryptamines during digestion — making oral activity possible without MAOI co-administration.[2] The 1981 date cited in some sources likely refers to unpublished laboratory work; no published record from that year has been identified.[2]
Characterization and documentation
Alexander Shulgin documented MiPT in TiHKAL (1997), entry #47, recording two synthetic routes, dosage ranges, and detailed self-experiment narratives.[3] He noted the compound's unusually cognitive character and its remarkable physical stability — the freebase resists air oxidation far better than most tryptamines.[3]
Modern status
MiPT appeared as a novel psychoactive substance in Europe around 2005 but has remained exceptionally rare.citation needed Unlike its ring-substituted relatives 5-MeO-MiPT and 5-MeO-DiPT, it has produced virtually no clinical or forensic reports.citation needed
The name MiPT follows standard tryptamine abbreviation conventions: "M" for methyl, "iPT" for isopropyltryptamine. It sits within a family sharing the MiPT suffix — 4-HO-MiPT (miprocin), 5-MeO-MiPT (moxy) — where ring substitution dramatically alters potency and character. The unsubstituted parent compound lacks the colorful nicknames of its relatives, reflecting its obscurity.citation needed
Chemistry[edit]
Structural class
MiPT belongs to the substituted tryptamine family — compounds built on an indole ring with an ethylamine side chain.[3] Its nitrogen carries an asymmetric pair of groups: one methyl and one isopropyl. The bulky isopropyl group shields the molecule from the enzyme that destroys DMT during digestion, granting MiPT oral activity that DMT lacks.[2][3]
Molecular properties
MiPT's molecular formula is C₁₄H₂₀N₂ (molecular weight 216.32 g/mol). The freebase has a melting point of 82–83 °C and is unusually resistant to air oxidation — most tryptamine freebases degrade quickly when exposed to light and oxygen.[3][6] It is the unsubstituted-ring parent in a series that includes 4-HO-MiPT and 5-MeO-MiPT.[2]
Pharmacology[edit]
Mechanism of action
MiPT partially activates serotonin receptors in the brain — it stimulates the receptor but not as forcefully as serotonin itself.[1] Unlike related tryptamines such as 5-MeO-MiPT, it shows no meaningful activity at a separate serotonin pathway linked to stimulation and anxiety reduction.[1][7] MiPT also enters neurons through the SERT and may accumulate inside the cell — what this contributes to the experience remains unknown.[8]
Oral activity
The isopropyl group on MiPT's nitrogen acts as a physical shield against the enzyme that destroys tryptamines during digestion.[3][2] This is why DMT — which lacks this protection — must be smoked or injected rather than taken orally.
Pharmacokinetics
No human studies have measured how MiPT is absorbed, distributed, or eliminated. Metabolism is inferred from the close structural analog 5-MeO-MiPT, involving liver enzymes CYP2D6 and CYP3A4.[9][10]inferred
Neuroscience[edit]
Where it acts
No neuroimaging data exist for MiPT. Based on its partial serotonin receptor activation,[1] its primary effects are expected in the prefrontal cortex — the region most densely packed with the relevant receptors.citation needed Activation there disrupts the brain's normal filtering of sensory and cognitive information, increasing crosstalk between regions that ordinarily operate independently.citation needed
MiPT's entry into neurons via the SERT[8] raises the additional possibility of effects through a separate signaling pathway inside the cell.[8] Whether this contributes meaningfully to the experience remains unknown.
Why it matters
One influential theory proposes that serotonin receptor activation loosens the brain's reliance on established expectations, allowing raw sensory input more influence over conscious experience.citation needed MiPT's cognitive-dominant, visually sparse profile puts this theory under pressure — it produces significant mental disruption without the perceptual distortion the theory typically predicts. Whether partial activation reaches the threshold needed to promote structural neural growth, as full psychedelics may, is also unresolved.[1]citation needed
- Does MiPT's partial agonism produce qualitatively different neural network disruption compared to full agonists like DMT?
- Is SERT-mediated intraneuronal accumulation pharmacologically relevant to MiPT's psychoactive effects, or negligible at achieved concentrations?
- What accounts for the cognitive-dominant, visual-sparse profile — the partial agonism ceiling, the absence of 5-HT₁A activity, or both?
Subjective Effects[edit]
MiPT is defined by what it does to thought rather than sight. The experience opens a clear, introspective space — ideas deepen, emotional resonance intensifies, and the visual world stays largely intact.[2][3] At higher amounts the cognitive depth increases further, but the geometric patterning typical of other tryptamines never arrives.
Among short-acting tryptamines, MiPT is less visually intense than DPT and less potent than 5-MeO-MiPT, occupying a quieter, more cognitively grounded niche.[1] Where perceptual distortion normally anchors the psychedelic experience, MiPT relies almost entirely on internal state and surroundings — making set and setting unusually determinative.
First published by Repke, Grotjahn, and Shulgin in 1985 as part of a systematic study of tryptamine oral activity, MiPT demonstrated that asymmetric N-alkylation could bypass monoamine oxidase degradation.[2] Shulgin expanded the characterization in TiHKAL (1997), documenting its dosage range and cognitive-dominant experiential profile.[3] MiPT remains one of the rarest tryptamine psychedelics in circulation, generating virtually no forensic or clinical literature.
Subjective effects include color brightening, auditory enhancement, cognitive intensification, and entheogenic ideation. The experience is defined by its cognitive-entheogenic emphasis — a clear, introspective space with notably minimal visual distortion compared to other tryptamines.[2][3] Anxiety, confusion, and restless body load are characteristic unsought effects.
MiPT produces no physical dependence; rapid tolerance develops after a single dose via downregulation, making compulsive use self-limiting.[4] The primary risks are psychological — anxiety, panic, and confusion — with serotonin syndrome risk escalating sharply when combined with MAOIs or serotonergic agents.[5] No controlled studies, toxicity data, or human pharmacokinetic parameters exist for MiPT — the current understanding rests entirely on structure-activity inference and a handful of self-experiment reports.
History[edit]
Discovery
Repke, Grotjahn, and Shulgin first described MiPT in 1985 in the Journal of Medicinal Chemistry, as part of a series synthesizing eight N-methyl-N-isopropyltryptamine analogs with varying ring substituents.[2] The study established a key principle: placing a bulky isopropyl group on the terminal amine nitrogen protected tryptamines from monoamine oxidase degradation, making them orally active without MAOI co-administration — a limitation that had defined DMT.[2] Multiple secondary sources cite 1981 as the date of first synthesis, but no published record from that year has been identified; the 1981 date likely refers to unpublished laboratory work.[2]
Characterization and documentation
Alexander Shulgin provided extended documentation of MiPT in TiHKAL: Tryptamines I Have Known and Loved (1997), entry #47.[3] The entry records two synthetic routes, establishes the oral dosage range at 10–25 mg with a duration of 3–4 hours, and includes detailed self-experiment narratives across multiple dose levels.[3] Shulgin noted the compound's unusual physical stability — the freebase resists air oxidation far better than most tryptamines.[3]
Modern status
MiPT appeared as a novel psychoactive substance in Europe by approximately 2005 but has remained exceptionally rare.citation needed Unlike its ring-substituted relatives 5-MeO-MiPT and 5-MeO-DiPT, which have generated forensic case literature, MiPT has produced virtually no clinical or forensic reports — consistent with its limited prevalence.citation needed
The name MiPT follows standard tryptamine abbreviation conventions: "M" for methyl, "iPT" for isopropyltryptamine. It sits within a family sharing the MiPT suffix — 4-HO-MiPT (miprocin), 5-MeO-MiPT (moxy) — where ring substitution dramatically alters potency and character. The unsubstituted parent compound lacks the colorful nicknames of its relatives, reflecting its obscurity.citation needed
Chemistry[edit]
Structural class
MiPT belongs to the substituted tryptamine family — compounds built on an indole ring connected to an ethylamine side chain at the 3-position. Its defining feature is an asymmetric N,N-dialkyl substitution: one methyl group and one isopropyl group on the terminal amine nitrogen.[3]
This asymmetry is pharmacologically decisive. The bulky isopropyl group shields the molecule from monoamine oxidase degradation during first-pass metabolism, granting oral bioavailability that the symmetrical N,N-dimethyl structural analog (DMT) lacks.[2][3] MiPT is the unsubstituted-ring parent in a series that includes 4-HO-MiPT and 5-MeO-MiPT.[2]
Molecular properties
| Molecular formula | C₁₄H₂₀N₂ |
| Molecular weight | 216.32 g/mol |
MiPT contains no chirality centers and exists as a single achiral species.
Physical properties
MiPT freebase is a colorless oil that spontaneously crystallizes, with a melting point of 82–83 °C.[3] The compound is unusually stable to air oxidation — a distinctive property among tryptamine freebases, which typically decompose rapidly when exposed to light and oxygen.[3][6] No solubility, partition coefficient, or degradation pathway data have been published.
Pharmacology[edit]
Mechanism of action
MiPT produces its psychedelic effects primarily through partial agonism at serotonin 5-HT₂A receptors.[1] It activates these receptors with moderate potency but does not reach the full signaling intensity of serotonin itself, producing partial rather than full activation.[1]
Notably, MiPT shows no meaningful activity at 5-HT₁A receptors[1] — contradicting earlier classifications and distinguishing it from 5-substituted tryptamines like 5-MeO-MiPT, which consistently activate 5-HT₁A.[7]
MiPT also enters neurons through the SERT (SERT) and VMAT2 (VMAT2), functioning as a substrate rather than a blocker at both.[8] This mechanism — analogous to how amphetamine enters neurons via the DAT — may allow intraneuronal accumulation, though the functional consequences remain unknown.[8]
Oral activity
MiPT's oral bioavailability is unusual for an unsubstituted tryptamine. The isopropyl group on the amine nitrogen provides steric protection against monoamine oxidase, preventing the rapid first-pass degradation that renders DMT orally inactive.[3][2]
Pharmacokinetics
No human pharmacokinetic studies exist for MiPT. Key parameters — time to peak blood levels, plasma half-life, bioavailability, and protein binding — have not been measured.
Metabolic pathways are inferred from the close structural analog 5-MeO-MiPT, whose primary routes include N-demethylation and hydroxylation, with additional N-oxide formation.[9] Enzyme involvement is inferred from related tryptamines, where CYP2D6 and CYP3A4 are the principal metabolizing enzymes.[10] Until substance-specific data are available, CYP2D6 and CYP3A4 involvement should be assumed for MiPT.inferred
Neuroscience[edit]
Where it acts
No neuroimaging or electrophysiological data exist for MiPT specifically. Based on its established 5-HT₂A partial agonism,[1] its primary neural effects are expected in the prefrontal cortex, where 5-HT₂A receptors are densely expressed.citation needed Activation of these receptors disrupts thalamocortical gating — the brain's filtering system for sensory and cognitive information — increasing cross-talk between brain regions that normally operate independently.citation needed
MiPT's substrate behavior at SERT and VMAT2[8] raises the additional possibility of intraneuronal sigma-1 receptor activation, which modulates calcium signaling and gene expression.[8] Whether this pathway contributes meaningfully to MiPT's effects is unknown.
Why it matters
The REBUS model proposes that 5-HT₂A agonism loosens the brain's reliance on established expectations, allowing raw sensory input greater influence on conscious experience.citation needed MiPT's cognitive-dominant, visual-sparse profile could test this model — the theory would need to explain substantial cognitive disruption with minimal perceptual distortion.
Psychedelics are increasingly recognized as psychoplastogens — compounds that promote structural neural growth. MiPT's partial agonism and biased signaling at 5-HT₂A[1] raise the question of whether partial activation reaches the threshold for neuroplastic effects.citation needed
- Does MiPT's partial agonism produce qualitatively different neural network disruption compared to full agonists like DMT?
- Is SERT-mediated intraneuronal accumulation pharmacologically relevant to MiPT's psychoactive effects, or negligible at achieved concentrations?
- What accounts for the cognitive-dominant, visual-sparse profile — the partial agonism ceiling, the absence of 5-HT₁A activity, or both?
Subjective Effects[edit]
MiPT delivers a psychedelic experience weighted heavily toward cognition and introspection, with remarkably little visual distortion compared to other tryptamines.[2][3] At lower doses, color brightening and auditory enhancement emerge alongside a stream of entheogenic ideation; higher doses deepen the cognitive effects without producing the geometric patterning typical of the class. Set and setting shape the experience more forcefully than with visually dominant psychedelics, where perceptual distortion provides a consistent anchor regardless of context.
Among short-acting tryptamines, MiPT occupies a niche distinct from DPT — similar duration but cleaner and more cognitively focused, without DPT's dissociative and visual intensity. Relative to 5-MeO-MiPT, the unsubstituted parent compound is less potent, shorter-acting, and produces a gentler version of the conceptual stimulation.[1]
Effect Grid
At common doses (10–20 mg oral), the characteristic MiPT profile manifests: considerable central stimulation, brightened colors, and enhanced appreciation for music. Cognitive effects predominate — increased associative thinking, conceptual fluidity, and a psychedelic headspace with entheogenic qualities. Visual distortion is notably minimal compared to other tryptamines; geometric patterning and visual hallucination are largely absent.
Physically, mild-to-moderate stimulation, pupil dilation, and possible jaw tension or restlessness are reported. Body load remains lighter than many classical tryptamines.
Duration is 3–4 hours with a manageable afterglow. Sleep may be difficult for 1–2 hours after effects subside.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual breathing · Color alteration · Tracers · Brightness alteration · Auditory enhancement · Light sensitivity · Sound sensitivity · After-images · Auditory distortion · Depth perception distortion · Environmental patterning · Holotropic state · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Spatial disorientation · Symmetrical texture repetition · Touch enhancement · Visual diffraction · Visual haze / noise · Visual morphing · Visual acuity enhancement · Auditory misinterpretation · Dreaming enhancement · Vestibular distortion · Visual melting · Visual processing acceleration · Peripheral misidentification · Synesthesia · Tinnitus · Visual recursion · External hallucinations · Internal hallucinations · Object transformations · Auditory hallucinations
Auditory enhancement · Light sensitivity · Sound sensitivity · After-images · Auditory distortion · Depth perception distortion · Environmental patterning · Holotropic state · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Spatial disorientation · Symmetrical texture repetition · Touch enhancement · Visual diffraction · Visual haze / noise · Visual morphing · Visual acuity enhancement · Auditory misinterpretation · Dreaming enhancement · Vestibular distortion · Visual melting · Visual processing acceleration · Peripheral misidentification · Synesthesia · Tinnitus · Visual recursion · External hallucinations · Internal hallucinations · Object transformations · Auditory hallucinations
Spontaneous body sensations · Wakefulness · Body high · Nausea · Muscle tension · Tingling / electric sensations · Vibrations / buzzing · Dry mouth · Appetite suppression · Breathing alteration · Heart rate perception changes · Laughter fits · Physical fatigue · Restlessness · Tactile euphoria · Bodily pressures · Body schema distortion · Dehydration sensation · Dizziness · Excessive sweating · Insomnia · Kundalini-like energy · Temperature dysregulation · Yawning · Abnormal heartbeat · Bruxism · Diarrhea · Headache · Involuntary body movements · Nystagmus (eye wobbles) · Trembling · Vomiting · Bodily dissociation · Tactile hallucination
Nausea · Muscle tension · Tingling / electric sensations · Vibrations / buzzing · Dry mouth · Appetite suppression · Breathing alteration · Heart rate perception changes · Laughter fits · Physical fatigue · Restlessness · Tactile euphoria · Bodily pressures · Body schema distortion · Dehydration sensation · Dizziness · Excessive sweating · Insomnia · Kundalini-like energy · Yawning · Abnormal heartbeat · Bruxism · Diarrhea · Headache · Involuntary body movements · Nystagmus (eye wobbles) · Trembling · Vomiting · Bodily dissociation · Tactile hallucination
Novelty enhancement · Immersion enhancement · Aesthetic enhancement · Cognitive euphoria · Introspection enhancement · Openness enhancement · Thought acceleration · Cognitive flexibility · Multiple thought streams · Creativity enhancement · Humor enhancement · Memory suppression · Cognitive fatigue · Cognitive impairment · Confusion · Focus suppression · Increased nature relatedness · Synchronicity · Thought disorganization · Thought loops · Analysis enhancement · Cognitive dysphoria · Information processing suppression · Language suppression · Memory fragmentation · Motivation suppression · Focus enhancement · Information processing enhancement · Language enhancement · Motivation enhancement
Introspection enhancement · Openness enhancement · Thought acceleration · Cognitive flexibility · Multiple thought streams · Creativity enhancement · Humor enhancement · Memory suppression · Cognitive fatigue · Cognitive impairment · Confusion · Focus suppression · Increased nature relatedness · Synchronicity · Thought disorganization · Thought loops · Analysis enhancement · Cognitive dysphoria · Information processing suppression · Language suppression · Memory fragmentation · Motivation suppression · Focus enhancement · Information processing enhancement · Language enhancement · Motivation enhancement
Simultaneous emotions · Anxiety · Empathy enhancement · Anxiety suppression · Catharsis · Anhedonia · Dysphoria · Irritability
Catharsis · Anhedonia · Dysphoria · Irritability
Communication suppression · Depersonalization · Social connection · Communication enhancement · Sociability enhancement · Ego inflation · Sociability suppression · Social disconnection · Boundary dissolution · Cognitive disconnection · Identity alteration · Ego dissolution · Telepathic feelings
Sociability enhancement · Ego inflation · Sociability suppression · Social disconnection · Boundary dissolution · Cognitive disconnection · Identity alteration · Ego dissolution · Telepathic feelings
Time cessation
Entity contact · Transpersonal memory access · Transpersonal visions · Voidness · Cessation · Death-rebirth sequence · Near-death experience
Cessation · Death-rebirth sequence · Near-death experience
Recursive awareness
Timeline
First alerts appear as a subtle shift in mental clarity and mild mood elevation. A light stimulant quality may be noticeable.
Cognitive stimulation builds steadily. Colors begin to brighten and music appreciation increases. Mild physical stimulation and pupil dilation emerge.
Maximum cognitive and entheogenic intensity. Thought acceleration, associative fluidity, and conceptual stimulation dominate. Color enhancement reaches its peak.
Cognitive intensity recedes gradually. Stimulation tapers and thought patterns return toward baseline. Residual mood elevation and reflective quality persist.
Mild residual mood elevation and reflective clarity may persist for 1–2 hours after subjective effects resolve. Sleep may be slightly delayed.
⚠ Do not drive or operate machinery for at least 4 hours after the experience ends, or until the following morning if dosing in the evening.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · DMT
Toxicity
No lethal dose, therapeutic index, or toxicity data exist for MiPT in any species.safety citation needed No case reports of overdose or adverse events specific to MiPT have been published.
Analog toxicology
Safety inferences draw on the close structural analog 5-MeO-MiPT. One forensic case involved acute agitation following 5-MeO-MiPT use, though multiple other drugs were present, making single-substance conclusions impossible.[9] Preclinical studies have assessed cardiovascular and motor effects of 5-MeO-MiPT in mice.[11]
Class-level risks
As a serotonin receptor agonist, MiPT carries risks typical of classical psychedelicsinferred:
- Cardiovascular stimulation: increased heart rate and blood pressure at higher doses
- Temperature dysregulation: overheating is possible, particularly with physical exertion or warm environments
- Serotonin syndrome: risk elevated when combined with serotonergic agents
Psychological risks
Anxiety, panic, paranoia, and confusion occur with all classical psychedelics and are expected with MiPT.safety citation needed Persistent perceptual changes after the experience have not been reported, but the evidence base is too thin to assess actual risk. People with personal or family histories of psychotic disorders or bipolar disorder face elevated risk of psychiatric destabilization.safety citation needed
Tolerance and dependence
MiPT does not produce physical dependence, and no withdrawal has been documented. Tolerance builds rapidly after a single dose — serotonin receptors in the frontal cortex downregulate, blunting the response to any repeat dose within days.[4]
This cross-tolerance extends to LSD, psilocybin, and DMT.[12] Tryptamine psychedelics may build tolerance somewhat more slowly than LSD-class compounds,[13] and rapid tolerance itself limits reinforcing properties.
Drug Interactions
MAOIs block the breakdown of MiPT while raising serotonin levels — the combination dramatically amplifies and prolongs effects and risks a life-threatening overheating and seizure response.[5] This applies to pharmaceutical MAOIs (phenelzine, tranylcypromine, moclobemide) and to β-carboline MAOIs in ayahuasca.
SSRIs also carry serotonin syndrome risk in combination with serotonin receptor agonists, and may blunt psychedelic effects through chronic downregulation.[5] Lithium combined with serotonergic psychedelics is associated with seizures and severe neurological reactions — a class-level absolute contraindication.safety citation needed Stimulants increase cardiovascular stress.[9] CYP2D6/CYP3A4 inhibitors may slow metabolism and increase exposure.inferred Cannabis is anecdotally reported to intensify effects unpredictably.citation needed
Contraindications
8 knownNo substance-specific contraindication studies exist — these are inferred from class pharmacology.
Absolute:
- Concurrent MAOI use — serotonin syndrome and dangerous potentiation
- Concurrent lithium therapy — seizure risk
- Personal history of psychotic disorders — psychosis precipitation
- Personal history of bipolar I disorder — manic episode triggering
Relative:
- Concurrent SSRI or SNRI use — serotonin syndrome risk and attenuated effects
- Family history of psychotic disorders — elevated vulnerability
- Heart conditions (high blood pressure, irregular heartbeat, heart failure) — cardiovascular stimulation at higher doses
- Pregnancy and breastfeeding — no safety data exist
- Liver impairment — inferred CYP2D6/CYP3A4 metabolism may produce elevated exposureinferred
Harm Reduction[edit]
Forms & Identification
MiPT is exceptionally rare and poorly documented in circulation. Misidentification is a significant risk — it could be confused with more potent relatives like 5-MeO-MiPT, which is active at lower doses and carries a different risk profile. Ehrlich reagent confirms tryptamine presence but cannot distinguish MiPT from its analogs; definitive identification requires laboratory analysis.[14]
Guidelines
- Test all material with Ehrlich reagent before use to confirm indole presence
- Use an accurate milligram scale — MiPT is active at 10 mg, making estimation dangerous
- Start at the low end of the dose range for first experiences with a new batch
- Allow a full experience to resolve before considering redosing — effects may develop slowly
- Keep the environment calm, familiar, and physically safe
- Have a sober sitter present, especially for unfamiliar dose ranges
- Stay hydrated but avoid excessive water intake
- Allow at least 7–14 days between sessions for full tolerance reset
Set & Setting
MiPT's cognitive-entheogenic character makes it unusually sensitive to mental preparation and environment.[3] Without strong visual anchoring, the experience is shaped primarily by internal state and external context. A calm, familiar setting with trusted companions provides the most supportive framework. First experiences benefit from a sober sitter who can offer grounding during periods of cognitive intensity.
Aftercare & integration. The cognitive-entheogenic character of MiPT means the experience may surface unfamiliar thoughts or emotional material that benefits from deliberate processing. Journaling within 24 hours helps capture insights before they fade. Conversations with trusted friends or a therapist experienced in psychedelic integration can help contextualize the experience.
Allow a full day of rest following a session. Eat well, sleep fully, and avoid demanding cognitive tasks. If distressing thoughts or perceptual changes persist beyond 48 hours, consult a mental health professional.
Recovery & Support
Classical psychedelics like MiPT carry low abuse liability — rapid tolerance and absence of withdrawal make compulsive use uncommon. If psychedelic use is becoming a way to avoid addressing underlying issues, or if frequency is increasing despite negative consequences, professional support is warranted. The Fireside Project (62-FIRESIDE) provides free psychedelic peer support. MAPS Integration List maintains a directory of therapists experienced with psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most MiPT experiences involve manageable anxiety or confusion that resolves within the duration. Seek immediate help if any of the following occur: sustained rapid heartbeat with chest pain, dangerously elevated body temperature (skin hot to the touch), seizure, loss of consciousness, severe agitation with risk of self-harm, or complete dissociation from reality with inability to communicate.
Immediate steps:
- Move the person to a quiet, safe space
- Call emergency services if symptoms are severe or worsening
- Keep the person cool if overheating — remove excess clothing, apply cool water
- Do not restrain unless there is immediate danger of self-harm
- Stay with the person and speak calmly
What to tell the dispatcher: Name the substance (MiPT, a tryptamine psychedelic), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
MiPT is not specifically scheduled in most countries, but its structural similarity to controlled tryptamines means it may fall under structural analog or generic provisions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not listed under the Controlled Substances Act. The Federal Analog Act (21 U.S.C. § 813) may apply if intended for human consumption, given structural and pharmacological similarity to Schedule I tryptamines. A January 2022 DEA proposal to schedule five related tryptamines (including 5-MeO-MiPT but not MiPT) was withdrawn in July 2022 following public comment challengescitation needed |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Captured by the generic tryptamine definition effective January 7, 2015. MiPT is explicitly named in secondary sources covering the generic clause[6] |
| Canada | Not specifically listed | Not listed in Schedule III (hallucinogens) of the Controlled Drugs and Substances Act as of 2025citation needed |
| Australia | Unconfirmed | May be captured under Schedule 9 (prohibited substance) of the Poisons Standard via generic tryptamine provisions, but explicit listing could not be verifiedcitation needed |
| China | Not specifically listed | 5-MeO-MiPT was listed as a controlled substance in September–October 2015. No specific data found for unsubstituted MiPT under Chinese regulationscitation needed |
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · DMT
Toxicity
No lethal dose, therapeutic index, or controlled toxicity data exist for MiPT in any species.safety citation needed No case reports of adverse events, poisoning, or overdose specific to MiPT have been published.
Analog toxicology
Safety inferences rely on the close structural analog 5-MeO-MiPT. One forensic case involved a man found naked and agitated on a public street following 5-MeO-MiPT use, though cocaine, cocaethylene, and methylphenidate were also present, making causal attribution impossible.[9] Preclinical assessment in mice has measured motor, sensory, and cardiorespiratory effects of 5-MeO-MiPT.[11]
Class-level risks
As a serotonin 2A receptor agonist, MiPT carries risks typical of the psychedelic classinferred:
- Cardiovascular stimulation: increased heart rate and blood pressure at higher doses
- Temperature dysregulation: overheating is possible, particularly with physical exertion or warm environments
- Serotonin syndrome: risk elevated when combined with serotonergic agents
Psychological risks
Acute psychological distress — anxiety, panic, paranoia, and confusion — occurs with all classical psychedelics and is expected with MiPT.safety citation needed No substance-specific prevalence data exist.
Hallucinogen persisting perception disorder (HPPD) has not been reported with MiPT, though the evidence base is too thin to assess actual risk.
Individuals with personal or family histories of psychotic disorders or bipolar disorder face elevated risk of psychosis or psychiatric destabilization with any 5-HT₂A agonist.safety citation needed
Tolerance and dependence
MiPT does not produce physical dependence. No withdrawal has been documented for MiPT or any closely related tryptamine.
Rapid tolerance develops after a single dose through downregulation of 5-HT₂A receptors in the frontal cortex.[4] Cross-tolerance extends to other serotonergic psychedelics including LSD, psilocybin, and DMT.[12]
Tryptamine-derived psychedelics may develop less tolerance than phenethylamine-derived psychedelics, suggesting MiPT's tolerance buildup could be somewhat less pronounced than LSD-class compounds.[13] Rapid tolerance itself limits reinforcing properties, further reducing abuse liability.
Drug Interactions
MAOIs: Both irreversible and reversible MAOIs would markedly potentiate and prolong MiPT's effects by blocking metabolic degradation while increasing serotonin availability. Serotonin syndrome risk is severe.[5] This applies to pharmaceutical MAOIs (phenelzine, tranylcypromine, moclobemide) and to β-carboline MAOIs in ayahuasca preparations.
SSRIs: Serotonin syndrome risk exists when combining any 5-HT₂A agonist with SSRIs.[5] SSRIs may also blunt psychedelic effects through chronic receptor downregulation.
Lithium: Lithium combined with serotonergic psychedelics is associated with seizures and severe neurological reactions.safety citation needed This is a class-level absolute contraindication.
Stimulants: Cocaine, amphetamines, or methylphenidate increase cardiovascular load. The 5-MeO-MiPT forensic case involved polydrug use with cocaine and methylphenidate.[9]
CYP2D6/CYP3A4 inhibitors: Based on inferred metabolic pathways, potent inhibitors of these enzymes could increase MiPT exposure and prolong effects.inferred
Cannabis: Anecdotally reported to intensify and prolong psychedelic effects unpredictably. No MiPT-specific data exist.citation needed
Contraindications
8 knownNo substance-specific contraindication studies exist. The following are inferred from class-level pharmacology.
Absolute:
- Concurrent MAOI use — serotonin syndrome and dangerous potentiation
- Concurrent lithium therapy — seizure risk
- Personal history of psychotic disorders — psychosis precipitation
- Personal history of bipolar I disorder — manic episode triggering
Relative:
- Concurrent SSRI or SNRI use — serotonin syndrome risk and attenuated effects
- Family history of psychotic disorders — elevated vulnerability
- Heart conditions (high blood pressure, irregular heartbeat, heart failure) — cardiovascular stimulation at higher doses
- Pregnancy and breastfeeding — no safety data exist
- Liver impairment — inferred CYP2D6/CYP3A4 metabolism may produce elevated exposureinferred
Harm Reduction[edit]
Forms & Identification
MiPT's rarity means limited data exist on forms in circulation. As an obscure tryptamine, misidentification and mislabeling are significant concerns — the compound could be confused with more potent ring-substituted relatives like 5-MeO-MiPT, which is active at lower doses and carries a different risk profile. Ehrlich reagent confirms tryptamine presence (indole ring) but cannot distinguish between MiPT and its analogs; definitive identification requires laboratory analysis.[14]
Guidelines
- Test all material with Ehrlich reagent before use to confirm indole presence
- Use an accurate milligram scale — MiPT is active at 10 mg, making estimation dangerous
- Start at the low end of the dose range for first experiences with a new batch
- Allow a full experience to resolve before considering redosing — effects may develop slowly
- Keep the environment calm, familiar, and physically safe
- Have a sober sitter present, especially for unfamiliar dose ranges
- Stay hydrated but avoid excessive water intake
- Allow at least 7–14 days between sessions for full tolerance reset
Set & Setting
MiPT's cognitive-entheogenic character makes it unusually sensitive to mental preparation and environment.[3] Without strong visual anchoring, the experience is shaped primarily by internal state and external context. A calm, familiar environment with trusted companions provides the most supportive framework. First experiences benefit from a sober sitter who can offer grounding and reassurance during periods of cognitive intensity.
Aftercare & integration. The cognitive-entheogenic character of MiPT means the experience may surface unfamiliar thoughts or emotional material that benefits from deliberate processing. Journaling within 24 hours helps capture insights before they fade. Conversations with trusted friends or a therapist experienced in psychedelic integration can help contextualize the experience.
Allow a full day of rest following a session. Eat well, sleep fully, and avoid demanding cognitive tasks. If distressing thoughts or perceptual changes persist beyond 48 hours, consult a mental health professional.
Recovery & Support
Classical psychedelics like MiPT carry low abuse liability — rapid tolerance and absence of withdrawal make compulsive use patterns uncommon. If psychedelic use is becoming a way to avoid addressing underlying issues, or if frequency is increasing despite negative consequences, professional support is warranted. The Fireside Project (62-FIRESIDE) provides free psychedelic peer support. MAPS Integration List maintains a directory of therapists experienced with psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most MiPT experiences involve manageable anxiety or confusion that resolves within the duration. Seek immediate help if any of the following occur: sustained rapid heartbeat with chest pain, dangerously elevated body temperature (skin hot to the touch), seizure, loss of consciousness, severe agitation with risk of self-harm, or complete dissociation from reality with inability to communicate.
Immediate steps:
- Move the person to a quiet, safe space
- Call emergency services if symptoms are severe or worsening
- Keep the person cool if overheating — remove excess clothing, apply cool water
- Do not restrain unless there is immediate danger of self-harm
- Stay with the person and speak calmly
What to tell the dispatcher: Name the substance (MiPT, a tryptamine psychedelic), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
MiPT occupies a legally ambiguous position in most jurisdictions. It is not specifically scheduled under most national drug control frameworks, but its structural relationship to scheduled tryptamines exposes it to structural analog or generic provisions in several countries.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not listed under the Controlled Substances Act. The Federal Analog Act (21 U.S.C. § 813) may apply if intended for human consumption, given structural and pharmacological similarity to Schedule I tryptamines. A January 2022 DEA proposal to schedule five related tryptamines (including 5-MeO-MiPT but not MiPT) was withdrawn in July 2022 following public comment challengescitation needed |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Captured by the generic tryptamine definition effective January 7, 2015. MiPT is explicitly named in secondary sources covering the generic clause[6] |
| Canada | Not specifically listed | Not listed in Schedule III (hallucinogens) of the Controlled Drugs and Substances Act as of 2025citation needed |
| Australia | Unconfirmed | May be captured under Schedule 9 (prohibited substance) of the Poisons Standard via generic tryptamine provisions, but explicit listing could not be verifiedcitation needed |
| China | Not specifically listed | 5-MeO-MiPT was listed as a controlled substance in September–October 2015. No specific data found for unsubstituted MiPT under Chinese regulationscitation needed |
Legal status is subject to change. The Federal Analog Act in the United States and generic substance definitions in the United Kingdom and potentially Australia create de facto control even where MiPT is not explicitly named. Possession or supply for human consumption may constitute a criminal offense in these jurisdictions regardless of explicit scheduling status.
Frequently asked questions
How long does MiPT last?
Total duration by route of administration — Oral: 3 – 4 hours; Insufflated: 2 – 3 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for MiPT?
Psychedex publishes a dosage table for MiPT on this page covering these routes of administration: oral, insufflated. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with MiPT?
The highest-severity documented interactions for MiPT: MAOIs (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Dopamine agonists (Dangerous), DXM (Dangerous), GHB, Baclofen (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is MiPT addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for MiPT: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, psilocybin, DMT, mescaline, 5-MeO-MiPT, 4-HO-MiPT, DPT. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4] ^abde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [5] ^abcMalcolm B, Thomas K (2022) Serotonin toxicity of serotonergic psychedelics — Psychopharmacology doi:10.1007/s00213-021-05876-x
- [6]
references
- [1]
- [2]
- [3]
- [4] ^abde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [5] ^abcMalcolm B, Thomas K (2022) Serotonin toxicity of serotonergic psychedelics — Psychopharmacology doi:10.1007/s00213-021-05876-x
- [6]